7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A clinician-reviewed guide to the legal status of compounded semaglutide (Ozempic), FDA shortage declarations, 503A/503B pharmacy rules, and what changes mean for patients in 2026.
A clinical comparison of how the FDA and EMA regulate Ozempic (semaglutide), covering approval timelines, label differences, boxed warnings, post-market surveillance, and safety monitoring frameworks.
A clinical review of Ozempic (semaglutide) FDA Adverse Event Reporting System signals, label updates, and post-market safety data through 2026.
A clinical review of Ozempic (semaglutide) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and ongoing label expansions.
Every FDA label change to Ozempic (semaglutide 0.5-2.0 mg) from 2020 through 2026, including new warnings, dose expansions, and post-market safety signals.
A complete guide to Ozempic's regulatory timeline, patent disputes, compounding litigation, and post-market safety findings. Reviewed by the HealthRX medical team.
A clinical review of Ozempic (semaglutide) regulatory history, current FDA label, post-market safety surveillance, and the next-generation GLP-1 pipeline from Novo Nordisk and competitors.